You are here

Article Text

Article menu
Download PDFPDF
Letter
Impact of anti-tumour necrosis factor therapy on the weight of patients with rheumatoid arthritis
  1. Nicola Alcorn1,
  2. Ann Tierney1,
  3. Olivia Wu2,
  4. Harper Gilmour2,
  5. Rajan Madhok1
  1. 1Glasgow Royal Infirmary, Centre Rheumatic Disease, Glasgow, UK
  2. 2Medical Statistics, Public Health and Health Policy, Glasgow University, Glasgow, UK
  1. Correspondence to Dr Nicola Alcorn, Glasgow Royal Infirmary, Centre Rheumatic Disease, Second Floor, Centre Block, Glasgow G4 0SF, UK; nicola.alcorn{at}ggc.scot.nhs.uk

https://doi.org/10.1136/ard.2009.122424

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    The role of tumour necrosis factor α (TNFα) in cachexia is established.1 More recent studies have found that adipocytes of obese animals and humans express higher levels of TNF than controls2 3; in this phenotype higher concentrations of TNFα are thought to limit further fat accumulation.4 5 We observed weight gain was becoming an increasing problem in some of our patients with rheumatoid arthritis (RA) given anti-TNF therapy. Several patients had raised this concern at review appointments and one even elected to discontinue anti-TNF treatment owing to weight gain. The authors therefore undertook a longitudinal retrospective review of …

    View Full Text

    Footnotes

    • Competing interests None.

    • Provenance and peer review Not commissioned; externally peer reviewed.